11 Apr
2021

Aon’s $400m IP fund; Nokia seals major Lenovo deal; LG touts smartphone patents; Influential senator's USPTO boss red lines; Sony IP strategy analysis; and much more

Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week

IAM Global Patent Litigation Survey

We want to know your views on the world’s major patent litigation hotspots and emerging jurisdictions in our patent litigation benchmarking survey. It takes 10 minutes to complete. Click here to take part. The findings will be revealed in the next IAM Special Report, to be published in Q2 2021.

The Long Read

Life sciences companies are frequently on the front line when it comes to being flexible on IP and pricing, says Ben Bourke of Womble Bond Dickinson. The most recent example of this is Moderna Therapeutics’ promise not to enforce patents relating to its approved covid-19 vaccine. Such a response makes sense and should be favoured over government-led initiatives to circumvent IP rights. Read more here

MONDAY 5th April

A look at Chinese companies’ semiconductor patent holdings suggests that their best bet for gaining globally relevant IP in the space is to acquire it. However, that leaves them with a big problem. Read more here

A new starting point for calculating cost awards in complex disputes could help to deter lengthy or unnecessary patent proceedings in Canada. Read more here

Aon launches $400 million fund designed for companies that have already been through their initial rounds of financing. Possession of a strong IP portfolio is one of the key assessment criteria. Read more here

TUESDAY 6th April

Acer does not have a track record of working with NPEs, but a recent assignment to Rock Creek Networks LLC has lit the fuse on a new assertion effort in the Western District of Texas. Read more here

Pharma companies must factor tough standing requirements into their IPR strategies at the USPTO after the Supreme Court declined to hear Argentum Pharmaceuticals v Novartis Pharmaceuticals. Read more here

In an exclusive interview, Thom Tillis, the Republican’s IP lead in the US Senate, reveals his USPTO director red lines and explains why Tiffany Cunningham is the right CAFC pick. Read more here

WEDNESDAY 7th April

Nokia and Lenovo have agreed a multi-year, multi-technology, patent cross-licence deal that will also see the Chinese company make a net balancing payment. Read more here

Apple has acquired at least 65 US patent assets from Panasonic, just weeks after picking up 24 more from the NPE Sun Patent Trust. Read more here

In an exclusive interview with IAM, former USPTO head Andrei Iancu amplifies his message that the US needs a national innovation policy and that policymakers need to wake up to SEPs. Read more here

THURSDAY 8th April

Despite well-documented problems with India’s Intellectual Property Appellate Board, its sudden closure by the government has drawn protests from IP practitioners. Read more here

A deal struck between BridgeBio Pharma and Helsinn Group is the latest evidence of the new opportunities for IP monetisation provided by hub-and-spoke life sciences companies. Read more here

With the semiconductor industry facing a supply crunch, Netlist has used recent courtroom gains to agree a purchase deal as well as a patent licence with long-time litigation opponent SK hynix. Read more here

FRIDAY 9th April

IAM has learnt that multiple Chinese companies have been approached by brokers offering to sell smartphone-related patents from LG. Read more here

Sony’s creative use of patents over the years has enabled multiple acquisitions and helped underpin a major business transformation. Read more here

The Fortress IP Group is back in the market for fresh capital and is seeking to build a fund that could reach a value of $900 million. Read more here

SATURDAY 10th April

In a split Senate, Thom Tillis’ determination to prevent any dilution of Andrei Iancu’s USPTO reforms will matter – a lot. Read more here

Joff Wild

Author | Editor-in-chief

[email protected]

Joff Wild